OTC · Health care

Avenue Therapeutics, Inc. (ATXI)

It posted a net loss of $2.8M. At June 30, 2026 it held $1.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.

Watch ATXI in 60 seconds

Price

$0.50

0.00% on the day · September 25, 2026

52-week range $0.15 to $0.97

Market cap

$1.6M

What Avenue Therapeutics, Inc. does

Avenue Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ATXI.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$1.4M	-$3.1M	-$2.9M	-$0.93	n/a
2024	$0	-$11.3M	-$11.7M	-$15.79	n/a
2023	n/a	-$14.5M	-$10.4M	-$73.48	n/a
2022	n/a	-$8M	-$3.6M	-$122.22	n/a
2021	n/a	-$3.7M	-$3.7M	-$16.50	n/a
2020	n/a	-$5.2M	-$5.2M	-$23.24	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 12, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 13, 2025. Not a date the company has announced. See the report calendar

Where ATXI ranks in Health care

Revenue$1.4M

#623 of 742 in Health care · Bottom 16%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Avenue Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 7, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.21 versus $0.11.
May 8, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.21 versus -$0.62.
March 30, 2026
Annual report 10-K · period to December 31, 2025Revenue was $1.4M; diluted EPS -$0.93 versus -$15.79.
February 23, 2026
Material agreement 8-K
February 17, 2026
Passive stake changed SCHEDULE 13G/A
December 31, 2025
Shareholder vote results 8-K
December 15, 2025
Form POS AM filing POS AM
December 15, 2025
Form RW filing RW
December 5, 2025
Proxy statement DEF 14A
November 18, 2025
Shareholder nomination deadline 8-K

Recent insider filings (Forms 3, 4 and 144): 9, the latest on April 2, 2025. Insider transactions on SEC

All filings on SEC EDGAR

Questions about ATXI

What does Avenue Therapeutics, Inc. do?

Avenue Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ATXI.

Is Avenue Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $2.8M.

When did Avenue Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare ATXI with

Compare ATXI with any company

Follow ATXI

Get an email when Avenue Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ATXI: get an email when it files

Where the numbers come from

Financial figures are the values Avenue Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.